Therapeutic impact of adult-type acute lymphoblastic leukemia regimens in B-cell/L3 acute leukemia and advanced-stage Burkitt'S lymphoma

Haematologica

Volumn 81, Issue 5, 1996, Pages 442-449

  Lerede, Teresa ^a   Bassan, Renato ^a   Rossi, Andrea ^a   Di Bona, Eros ^b   Rossi, Giuseppe ^c   Pogliani, Enrico M ^d   Motta, Teresio ^a   Torri, Valter ^e   Buelli, Maurizio ^a   Comotti, Benedetto ^a   Viero, Piera ^a   Rambaldi, Alessandro ^a   Cortelazzo, Sergio ^a   Rodeghiero, Francesco ^b   Barbui, Tiziano ^a  

^a OSPEDALI RIUNITI   (Italy)

^b Ospedale Civile Di Vicenza   (Italy)

^c SPEDALI CIVILI   (Italy)

^d SAN GERARDO HOSPITAL   (Italy)

^e Ist Ric Farmacologice 'M N ^*  (Italy)

Author keywords

Adults; B ALL; Burkitt's lymphoma; Treatment

Indexed keywords

CIPROFLOXACIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; NYSTATIN; PAROMOMYCIN;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; B CELL LEUKEMIA; BURKITT LYMPHOMA; CANCER SURVIVAL; CHEMOPROPHYLAXIS; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; CHILD; FEMALE; HUMANS; LEUKEMIA, B-CELL, ACUTE; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0030321742     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Hoelzer D, Ludwig W-D, Thiel E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996; 87: 495-508.
2. 3 ALL) in adults: a report of 18 cases. Br J Haematol 1989; 71:371-6.
3. Patte C, Michon J, Frappaz D, et al. Therapy of Burkitt and other B-cell acute lymphoblastic leukaemia and lymphoma: experience with the LMB protocol of the SFOP (French Paediatric Oncology Society) in children and adults. Baillière's Clin Haematol 1994; 7:339-48.
4. GIMEMA Cooperative Group. GIMEMA ALL 0183: a multicentric study on adult acute lymphoblastic leukaemia in Italy. Br J Haematol 1989; 71:377-86.
5. Ellison RR, Mick R, Cuttner J, et al. The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B. J Clin Oncol 1991; 9:2002-15.
6. Linker CA, Levitt LJ, O'Donnell M, Forman SJ, Ries CA. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood 1991; 78:2814-22.
7. Fière D, Lepage E, Sebban C, et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. J Clin Oncol 1993; 11:1990-2001.
8. Bassan R, Battista R, Rohatiner AZR, et al. Treatment of adult acute lymphoblastic leukaemia (ALL) over a 16-year period. Leukemia 1992; 6 (Suppl 2):186-90.
9. Bassan R, Battista R, Montaldi A, et al. Reinforced HEAV'D therapy for adult acute lymphoblastic leukemia: improved results and revised prognostic criteria. Hematol Oncol 1993; 11:169-77.
10. Bassan R, Battista R, Viero P, et al. Intensive therapy for adult acute lymphoblastic leukemia: preliminary results of the idarubicin/vincristine/L-asparaginase/prednisolone regimen. Semin Oncol 1993; 20:(suppl. 8)39-46.
11. th annual meeting of the European Group for Bone Marrow Transplantation, 1994: Extended Abstracts, 7.
12. Bassan R, Rambaldi A, Viero P, Borleri G, Barbui T. Integrated use of morphology, cytochemistry, and immune marker analysis to identify acute leukaemia subtypes. Haematologica 1989; 74:487-90.
13. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. Br J Haematol 1976; 33: 451-8.
14. Magrath IT, Jain V, Jaffe ES. Small noncleaved cell lymphoma. In: Knowles DM, ed. Neoplastic hematopathology, Baltimore:Williams & Wilkins, 1992:749-72.
15. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging. Cancer Res 1971; 31:1860-1.
16. Murphy SB, Fairclough DL, Hutchison RE, Berard CW. Non-Hodgkin's lymphoma of childhood: an analysis of the histology, staging, and response to treatment in 338 cases in a single institution. J Clin Oncol 1989; 7:186-93.
17. Magrath IT, Janus C, Edwards BK, et al. An effective therapy for both undifferentiated (including Burkitt's) lymphoma and lymphoblastic lymphoma in children and young adults. Blood 1984; 63:1102-11.
18. Hoelzer D, Thiel E, Ludwig WD, et al. Follow-up of the first two successive German multicentre trials for adult ALL (01/81 and 02/84). Leukemia 1993; 7(Suppl 2):S130-4.
19. Cohen LF, Balow JE, Magrath IT, Poplack DG, Ziegler JL. Acute tumor lysis syndrome-a review of 37 patients with Burkitt's lymphoma. Am J Med 1980; 68:486-91.
20. Bassan R, Lerede T, Rambaldi A, Buelli M, Viero P, Barbui T. The use of anthracyclines in adult acute lymphoblastic leukemia. Haematologica 1995; 80:280-91.
21. Ross D, Tong Y, Comblatt B. Idarubicin (IDA) is less vulnerable to transport-mediated multidrug resistance (MDR) than its metabolite idarubicinol (IDAol) or daunorubicin (DNR) (Abstract). Blood 1993; 82(Suppl 1):257a.
22. Goasguen JE, Dossot J-M, Bennett JM, Fauchet R. Multidrug resistance (MDR) associated P-170 glycoprotein is correlated to the cytology in ALL. Blood 1992; 80(Suppl 1):204a.
23. Ames MM, Spreafico F. Selected pharmacologic characteristics of idarubicin and idarubicinol. Leukemia 1992; 6(Suppl 1):70-5.
24. Murphy SB, Bowman WP, Abromowitch M, et al. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol 1986; 4:1732-9.
25. Sweetenham JW, Pearce R, Taghipour G, Goldstone AH. Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma (NHL)-Favourable outcome for patients undergoing high dose therapy and autologous stem cell transplantation (ASCT) in first remission or chemosensitive relapse: results from EBMT (Abstract). Blood 1995; 86(Suppl 1):211a.
26. Reid JM, Pendergrass TW, Krailo MD, et al. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients. A Children's Cancer Study Group report. Cancer Res 1990; 50: 6526-8.